These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31500893)

  • 1. Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.
    Olawaiye AB; Leath CA
    Gynecol Oncol; 2019 Nov; 155(2):365-373. PubMed ID: 31500893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy of uterine clear cell carcinoma: a review.
    Xu Y; Hanna RK; Elshaikh MA
    Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.
    Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A
    J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.
    Thomas M; Mariani A; Wright JD; Madarek EO; Powell MA; Mutch DG; Podratz KC; Dowdy SC
    Gynecol Oncol; 2008 Feb; 108(2):293-7. PubMed ID: 18096208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Armbruster SD; Previs R; Soliman PT; Westin SN; Fellman B; Jhingran A; Fleming ND
    Gynecol Oncol; 2019 Aug; 154(2):328-332. PubMed ID: 31221496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis.
    Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and Role of Adjuvant Radiotherapy and Chemotherapy for Uterine Clear Cell Carcinoma: A National Cancer Data Base Analysis.
    Xu KM; Gill BS; Balasubramani GK; Sukumvanich P; Kelley JL; Beriwal S
    Int J Gynecol Cancer; 2016 Mar; 26(3):472-82. PubMed ID: 26825837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
    Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
    Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.
    Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM
    Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.
    Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM
    Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
    Rauh-Hain JA; Costaaggini I; Olawaiye AB; Growdon WB; Horowitz NS; del Carmen MG
    Eur J Gynaecol Oncol; 2010; 31(3):284-7. PubMed ID: 21077469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
    Boren TP; Miller DS
    Womens Health (Lond); 2010 Nov; 6(6):789-95. PubMed ID: 21118038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
    Xu MJ; Chu C; Rubin S; Lin LL
    Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
    Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
    Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
    Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.